Unknown

Dataset Information

0

The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.


ABSTRACT: Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents.

SUBMITTER: Chrvala CA 

PROVIDER: S-EPMC3474424 | biostudies-other | 2012 Aug

REPOSITORIES: biostudies-other

altmetric image

Publications

The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.

Chrvala Carole Alison CA  

P & T : a peer-reviewed journal for formulary management 20120801 8


Four recently approved drugs (cabazitaxel, sipuleucel-T, abiraterone, and denosumab), along with emerging therapies, bone-building therapies, hormonal treatments, and immunotherapies, have all demonstrated promise in advanced prostate cancer. It appears that the best outcomes will be achieved from the sequential use of multiple agents. ...[more]

Similar Datasets

| S-EPMC3739642 | biostudies-literature
| S-EPMC3425086 | biostudies-literature
| S-EPMC4176261 | biostudies-literature
| S-EPMC3539272 | biostudies-literature
| S-EPMC6204864 | biostudies-literature
| S-EPMC8157020 | biostudies-literature
| S-EPMC6849387 | biostudies-literature
| S-EPMC6712455 | biostudies-literature
| S-EPMC5703947 | biostudies-literature
| S-EPMC3398088 | biostudies-literature